Huang, Y.-C., Morris, P., Owens, R., Guardia, C., Keller, S., Belloso, W., … Simonson, S. (2025). Lucinactant, A Synthetic Surfactant For The Treatment Of Acute Respiratory Distress Syndrome Caused By Covid-19: a Phase 1/2A trial (Preprint). JMIR Formative Research. https://doi.org/10.2196/77315

Huang, Yuh-Chin, Peter Morris, Robert Owens, Carlos Guardia, Steven Keller, Waldo Belloso, Timothy Gregory, Lawrence Weinstein, Phillip Simmons, and Steven Simonson. “Lucinactant, A Synthetic Surfactant For The Treatment Of Acute Respiratory Distress Syndrome Caused By Covid-19: a Phase 1/2A trial (Preprint).” JMIR Formative Research, May 11, 2025. https://doi.org/10.2196/77315.

Huang Y-C, Morris P, Owens R, Guardia C, Keller S, Belloso W, et al. Lucinactant, A Synthetic Surfactant For The Treatment Of Acute Respiratory Distress Syndrome Caused By Covid-19: a Phase 1/2A trial (Preprint). JMIR Formative Research. 2025 May 11;

Huang, Yuh-Chin, et al. “Lucinactant, A Synthetic Surfactant For The Treatment Of Acute Respiratory Distress Syndrome Caused By Covid-19: a Phase 1/2A trial (Preprint).” JMIR Formative Research, JMIR Publications Inc., May 2025. Crossref, doi:10.2196/77315.

Huang Y-C, Morris P, Owens R, Guardia C, Keller S, Belloso W, Gregory T, Weinstein L, Simmons P, Simonson S. Lucinactant, A Synthetic Surfactant For The Treatment Of Acute Respiratory Distress Syndrome Caused By Covid-19: a Phase 1/2A trial (Preprint). JMIR Formative Research. JMIR Publications Inc.; 2025 May 11;